[Molecular-targeted therapy for neurodegenerative diseases]

Area of Science:

• Neurodegenerative disease research
• Molecular targeted therapy
• Clinical neurology

Background:

• Neurodegenerative diseases were previously considered incurable.
• Recent advances in cellular and animal models offer insights into disease pathogenesis.
• Molecular targeted therapy presents a challenging yet promising avenue for neurodegenerative disorders.

Purpose of the Study:

• To explore the potential of molecular targeted therapy for neurodegenerative diseases.
• To highlight the development of androgen deprivation therapy for spinal and bulbar muscular atrophy (SBMA) as a case study.
• To emphasize the importance of basic science understanding and clinical trial design.

Main Methods:

• Analysis of cellular and animal models for neurodegenerative disease pathogenesis.
• Investigating the role of testosterone as the androgen receptor (AR) ligand in SBMA.
• Translating findings from SBMA mouse models to clinical trials.

Main Results:

• Testosterone plays a key role in SBMA neurodegeneration.
• Androgen deprivation therapy demonstrated significant success in SBMA mouse models.
• Successful translation of therapy from preclinical models to Phase 2 and Phase 3 clinical trials.

Conclusions:

• Molecular targeted therapy is a critical frontier in neurodegenerative disease treatment.
• Understanding disease pathophysiology is essential for developing effective therapies.
• Androgen deprivation therapy for SBMA represents a successful model for clinical translation.